- Home
- NKTR
NKTR
Nektar Therapeutics
as 04-18-2025 1:40pm EST
Nektar Therapeutics is a biopharmaceutical company. It has wholly-owned research and development pipeline of investigational medicines in oncology, immunology, and virology as well as a portfolio of approved partnered medicines. In oncology, The company is focused on activating the immune system natural tumor-fighting mechanisms, and it will be studying several immuno-oncology drug candidates in the clinic for a variety of cancer indications. In immunology, it is focused on addressing imbalances in the immune system to restore the body's self-tolerance mechanisms and achieve immune homeostasis. In virology, the company believes selective immuno-modulators can be useful in addressing viral infections in people. The group derives revenue from the United States and the Rest of the World.
| Founded: | 1990 | Country: | United States |
| Employees: | N/A | City: | SAN FRANCISCO |
| Market Cap: | 160.4M | IPO Year: | 1994 |
| Target Price: | $4.92 | AVG Volume (30 days): | 2.8M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 6 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.58 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.43 - $1.93 | Next Earning Date: | 05-08-2025 |
| Revenue: | $98,427,000 | Revenue Growth: | 9.21% |
| Revenue Growth (this year): | -24.38% | Revenue Growth (next year): | -5.84% |
Stock Insider Trading Activity of Nektar Therapeutics (NKTR)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Wilson Mark Andrew | NKTR | Chief Legal Officer | Feb 19 '25 | Sell | $1.01 | 11,040 | $11,150.40 | 324,292 | |
| ROBIN HOWARD W | NKTR | President & CEO | Feb 19 '25 | Sell | $1.01 | 23,774 | $24,011.74 | 1,086,901 | |
| Zalevsky Jonathan | NKTR | Chief R&D Officer | Feb 19 '25 | Sell | $1.01 | 10,300 | $10,403.00 | 316,604 |
Latest Nektar Therapeutics News
NKTR Breaking Stock News: Dive into NKTR Ticker-Specific Updates for Smart Investing
GuruFocus.com
8 days ago
Jefferies Upgrades Nektar Therapeutics to Buy, Doubles Price Target to $2.00
MT Newswires
8 days ago
Nektar Therapeutics Shares Rise After Upgrade From Jefferies
Zacks
8 days ago
Why Is Nektar (NKTR) Down 38.8% Since Last Earnings Report?
MT Newswires
8 days ago
Jefferies Upgrades Nektar Therapeutics to Buy From Hold, Adjusts Price Target to $2 From $1
MT Newswires
22 days ago
Nektar Therapeutics Files $300 Million Mixed Shelf
Insider Monkey
a month ago
Nektar Therapeutics (NKTR): Among Stocks Wall Street Is Calling Bullish Amid Market Turmoil
PR Newswire
a month ago
Nektar Therapeutics to Participate in the H.C. Wainwright 3rd Annual Autoimmune & Inflammatory Disease Virtual Conference
MT Newswires
a month ago
Nektar Therapeutics Shares Rise After Upgrade From Oppenheimer
Compare NKTR vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "NKTR Nektar Therapeutics - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.